Mylan-Biocon''s Biosimilar Cancer Drug Comparable To Roche''s Herceptin: Study - Nasdaq

Financial Express

Mylan-Biocon''s Biosimilar Cancer Drug Comparable To Roche''s Herceptin: Study Nasdaq and its Indian partner Biocon Ltd., is comparable to Roche Holding AG's branded Trastuzumab, a study, dubbed HERITAGE, confirmed. Trastuzumab, sold under the brand name Herceptin, is indicated for the treatment of HER2-positive metastatic breast ... Mylan-Biocon's Biosimilar Cancer Drug Comparable To Roche's Herceptin: StudyRTT News 'Comparable' Efficacy and Safety for Trastuzumab BiosimilarMedscape Mylan, Biocon's PhIII success for Herceptin knockoff threatens anchor drug for RocheFierceBiotech Wall Street Journal -NH Voice -Clinical Oncology News -International Business Times, India Edition all 54 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNEMlVN09wsBr1X4QgU1i4USIC0Iyw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779126286493&ei=EFZVV5CJF4e13gGHraPoCQ&url=http://www.nasdaq.com/article/mylanbiocons-biosimilar-cancer-drug-comparable-to-roches-herceptin-study-20160606-00043
via IFTTT